SEB Asset Management AB Takes Position in United Therapeutics Corporation $UTHR

SEB Asset Management AB bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 17,731 shares of the biotechnology company’s stock, valued at approximately $10,514,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Arjuna Capital increased its holdings in United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares in the last quarter. Sage Rhino Capital LLC lifted its stake in shares of United Therapeutics by 5.1% during the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC boosted its position in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after buying an additional 24 shares during the period. Independent Advisor Alliance boosted its position in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the period. Finally, Kera Capital Partners Inc. grew its stake in shares of United Therapeutics by 6.1% in the first quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock valued at $279,000 after buying an additional 27 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on UTHR. Royal Bank Of Canada raised their target price on United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Finally, Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $644.82.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $576.93, for a total transaction of $5,769,300.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,890,130.68. This trade represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 545,243 shares of company stock worth $305,155,272. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Stock Down 1.2%

Shares of NASDAQ UTHR opened at $529.34 on Tuesday. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The business has a 50 day moving average price of $551.57 and a two-hundred day moving average price of $530.56. The firm has a market cap of $22.47 billion, a PE ratio of 19.54, a price-to-earnings-growth ratio of 1.79 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the company earned $6.63 earnings per share. On average, analysts anticipate that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.